AMRN Amarin Corp

RNS Number:2389B
Amarin Corporation Plc
31 July 2007



                             AMARIN CORPORATION PLC


LONDON, United Kingdom, July 31, 2007 Amarin Corporation plc (the "Company") has
made a block listing application to the London Stock Exchange and the Irish
Stock Exchange in respect of 820,343 ordinary shares of #0.05 each ("Ordinary
Shares") in the capital of the Company to be admitted to trading on AIM and IEX,
of which 175,000 Ordinary Shares are issuable from time to time following the
exercise of warrants issued to Neurostat Pharmaceuticals Inc on April 27, 2007,
615,343 Ordinary Shares are issuable from time to time following the exercise of
warrants issued in a registered direct offering of the Company's Ordinary Shares
on June 1, 2007, and 30,000 Ordinary Shares are issuable from time to time
following the exercise of warrants issued to Proseed Capital Holdings CVA on
June 21, 2007.


About Amarin

Amarin is committed to improving the lives of patients suffering from diseases
of the central nervous system.  Our goal is to be a leader in the research,
development and commercialization of novel drugs that address unmet patient
needs.

Amarin's core development pipeline includes, in addition to Miraxion for several
therapeutic indications, four other key development programs in Parkinson's
disease, epilepsy seizures, memory and cognition and our proprietary
pre-clinical combinatorial lipid program.

Amarin has its primary stock market listing in the U.S. on NASDAQ ("AMRN") and
secondary listings in the U.K. and Ireland on AIM ("AMRN") and IEX ("H2E"),
respectively.

For press releases and other corporate information, visit the Amarin website at
www.amarincorp.com.  Information on our website does not form part of this press
release.


Contacts:

Amarin                                     +44 (0) 207 907 2442
Rick Stewart                               Chief Executive Officer
Alan Cooke                                 President & Chief Financial Officer
investor.relations@amarincorp.com

Investors:

Lippert/Heilshorn & Associates, Inc.       +1 212 838 3777
Kim Golodetz
Anne Marie Fields

Media:
Powerscourt                                +44 (0) 207 250 1446
Rory Godson
Victoria Brough

Davy
Fergal Meegan                              +353 (0) 1 679 6363



                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

LISUAVVRBSRBOAR

Amarin (LSE:AMRN)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025

Amarin (LSE:AMRN)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025